Krystal Biotech, Inc.
http://www.krystalbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Krystal Biotech, Inc.
The ‘Haves And Have-Nots’ Are Becoming Clearer In Cell And Gene Therapy
2023 saw a number of gene therapy companies go to the wall, but those that can combine clinical significance and commercial success can build sustainable businesses.
Keeping Track: Regeneron’s Bispecific Bid, More Regenerative Medicine BLAs, And Vadadustat Returns
Highlights of recent submissions for approval from the Pink Sheet’s US FDA Performance Tracker
A 3-Month Delay For A Better Label: US FDA User Fee Goal Extensions Are Usually Good News
Pink Sheet analysis finds big jump in the share of novel approvals that received PDUFA extensions, largely driven by clinical and safety data submissions.
Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Jeune, Inc.
- Jeune Aesthetics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice